How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "1770"
  ["article_id"]=>
  string(4) "1770"
  [1]=>
  string(52) "The first WuXi Healthcare Forum opens in ShanghaiHR3"
  ["article_title"]=>
  string(52) "The first WuXi Healthcare Forum opens in ShanghaiHR3"
  [2]=>
  string(3337) "
Driven by cutting-edge technology, favorable polices and rising venture capital, the global healthcare industry is facing unprecedented opportunities, but also, considerable challenges. The WuXi Healthcare Forum provides a platform to aggregate global expertise and is designed to promote international convergence and cooperation. Through the exchange of knowledge, experience and insights we will empower the continued growth of the healthcare ecosystem.
This two-day forum includes 20 sessions, with a central focus on "medicines for global impact" and "the new healthcare ecosystem". Over 90 guest speakers will deliver cutting-edge insights on global cooperation in the healthcare industry in order to achieve the next disruptive innovation. The agenda addresses the establishment of an innovative ecosystem, the improvement of efficiency in new drug R&D, and the affordability and accessibility of healthcare products.
Alongside the world-class content, the forum features a special CEO roundtable program, which will showcase 200 innovative companies at the precipice of healthcare innovation.
In parallel to the Forum, partners including Huatai Securities, China Renaissance, Fangda Partners, Goldman Sachs, Morgan Stanley and Deloitte will hold several side events, where the participants can exchange their ideas on trends in healthcare development and popular investment strategies.
"We extend our warmest welcome to all our distinguished guests," said Dr. Ge Li, Chairman of WuXi AppTec Group, "This is a forum that belongs to everyone in the global healthcare ecosystem. It is a platform of knowledge, wisdom, and learning to provide the key points to success, and just as crucially, the lessons we can learn from failures of the past. It is my hope that more people will participate in contributing to the prosperity of the healthcare ecosystem, and we can take a step closer to realizing the shared dream of WuXi, and the whole industry that 'every drug can be made, and every disease can be treated'."
About WuXi AppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and data platform, in-vitro and clinical diagnostics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."
SOURCE WuXi AppTec
"
  ["short_description"]=>
  string(3337) "
Driven by cutting-edge technology, favorable polices and rising venture capital, the global healthcare industry is facing unprecedented opportunities, but also, considerable challenges. The WuXi Healthcare Forum provides a platform to aggregate global expertise and is designed to promote international convergence and cooperation. Through the exchange of knowledge, experience and insights we will empower the continued growth of the healthcare ecosystem.
This two-day forum includes 20 sessions, with a central focus on "medicines for global impact" and "the new healthcare ecosystem". Over 90 guest speakers will deliver cutting-edge insights on global cooperation in the healthcare industry in order to achieve the next disruptive innovation. The agenda addresses the establishment of an innovative ecosystem, the improvement of efficiency in new drug R&D, and the affordability and accessibility of healthcare products.
Alongside the world-class content, the forum features a special CEO roundtable program, which will showcase 200 innovative companies at the precipice of healthcare innovation.
In parallel to the Forum, partners including Huatai Securities, China Renaissance, Fangda Partners, Goldman Sachs, Morgan Stanley and Deloitte will hold several side events, where the participants can exchange their ideas on trends in healthcare development and popular investment strategies.
"We extend our warmest welcome to all our distinguished guests," said Dr. Ge Li, Chairman of WuXi AppTec Group, "This is a forum that belongs to everyone in the global healthcare ecosystem. It is a platform of knowledge, wisdom, and learning to provide the key points to success, and just as crucially, the lessons we can learn from failures of the past. It is my hope that more people will participate in contributing to the prosperity of the healthcare ecosystem, and we can take a step closer to realizing the shared dream of WuXi, and the whole industry that 'every drug can be made, and every disease can be treated'."
About WuXi AppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and data platform, in-vitro and clinical diagnostics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."
SOURCE WuXi AppTec
"
  [3]=>
  string(3337) "
Driven by cutting-edge technology, favorable polices and rising venture capital, the global healthcare industry is facing unprecedented opportunities, but also, considerable challenges. The WuXi Healthcare Forum provides a platform to aggregate global expertise and is designed to promote international convergence and cooperation. Through the exchange of knowledge, experience and insights we will empower the continued growth of the healthcare ecosystem.
This two-day forum includes 20 sessions, with a central focus on "medicines for global impact" and "the new healthcare ecosystem". Over 90 guest speakers will deliver cutting-edge insights on global cooperation in the healthcare industry in order to achieve the next disruptive innovation. The agenda addresses the establishment of an innovative ecosystem, the improvement of efficiency in new drug R&D, and the affordability and accessibility of healthcare products.
Alongside the world-class content, the forum features a special CEO roundtable program, which will showcase 200 innovative companies at the precipice of healthcare innovation.
In parallel to the Forum, partners including Huatai Securities, China Renaissance, Fangda Partners, Goldman Sachs, Morgan Stanley and Deloitte will hold several side events, where the participants can exchange their ideas on trends in healthcare development and popular investment strategies.
"We extend our warmest welcome to all our distinguished guests," said Dr. Ge Li, Chairman of WuXi AppTec Group, "This is a forum that belongs to everyone in the global healthcare ecosystem. It is a platform of knowledge, wisdom, and learning to provide the key points to success, and just as crucially, the lessons we can learn from failures of the past. It is my hope that more people will participate in contributing to the prosperity of the healthcare ecosystem, and we can take a step closer to realizing the shared dream of WuXi, and the whole industry that 'every drug can be made, and every disease can be treated'."
About WuXi AppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and data platform, in-vitro and clinical diagnostics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."
SOURCE WuXi AppTec
"
  ["description"]=>
  string(3337) "
Driven by cutting-edge technology, favorable polices and rising venture capital, the global healthcare industry is facing unprecedented opportunities, but also, considerable challenges. The WuXi Healthcare Forum provides a platform to aggregate global expertise and is designed to promote international convergence and cooperation. Through the exchange of knowledge, experience and insights we will empower the continued growth of the healthcare ecosystem.
This two-day forum includes 20 sessions, with a central focus on "medicines for global impact" and "the new healthcare ecosystem". Over 90 guest speakers will deliver cutting-edge insights on global cooperation in the healthcare industry in order to achieve the next disruptive innovation. The agenda addresses the establishment of an innovative ecosystem, the improvement of efficiency in new drug R&D, and the affordability and accessibility of healthcare products.
Alongside the world-class content, the forum features a special CEO roundtable program, which will showcase 200 innovative companies at the precipice of healthcare innovation.
In parallel to the Forum, partners including Huatai Securities, China Renaissance, Fangda Partners, Goldman Sachs, Morgan Stanley and Deloitte will hold several side events, where the participants can exchange their ideas on trends in healthcare development and popular investment strategies.
"We extend our warmest welcome to all our distinguished guests," said Dr. Ge Li, Chairman of WuXi AppTec Group, "This is a forum that belongs to everyone in the global healthcare ecosystem. It is a platform of knowledge, wisdom, and learning to provide the key points to success, and just as crucially, the lessons we can learn from failures of the past. It is my hope that more people will participate in contributing to the prosperity of the healthcare ecosystem, and we can take a step closer to realizing the shared dream of WuXi, and the whole industry that 'every drug can be made, and every disease can be treated'."
About WuXi AppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and data platform, in-vitro and clinical diagnostics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."
SOURCE WuXi AppTec
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(5) "Admin"
  ["added_by"]=>
  string(5) "Admin"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  NULL
  ["rss_id"]=>
  NULL
  [14]=>
  string(79) "https://pharmaxcareers.com/The-first-WuXi-Healthcare-Forum-opens-in-ShanghaiHR3"
  ["blog_url"]=>
  string(79) "https://pharmaxcareers.com/The-first-WuXi-Healthcare-Forum-opens-in-ShanghaiHR3"
  [15]=>
  string(19) "2019-03-06 14:21:16"
  ["add_date"]=>
  string(19) "2019-03-06 14:21:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-06 14:21:16"
  ["create_at"]=>
  string(19) "2019-03-06 14:21:16"
  [19]=>
  string(52) "the_first_wuxi_healthcare_forum_opens_in_shanghaihr3"
  ["slug"]=>
  string(52) "the_first_wuxi_healthcare_forum_opens_in_shanghaihr3"
}

The first WuXi Healthcare Forum opens in ShanghaiHR3

Driven by cutting-edge technology, favorable polices and rising venture capital, the global healthcare industry is fa

array(40) {
  [0]=>
  string(4) "1984"
  ["article_id"]=>
  string(4) "1984"
  [1]=>
  string(63) "FDA Says 505(q) Petitions Pull Resources from Safety Activities"
  ["article_title"]=>
  string(63) "FDA Says 505(q) Petitions Pull Resources from Safety Activities"
  [2]=>
  string(158) "&#nl        Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said"
  ["short_description"]=>
  string(158) "&#nl        Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said"
  [3]=>
  string(193) "&#nl        Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said in a report to Congress.&#nl      "
  ["description"]=>
  string(193) "&#nl        Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said in a report to Congress.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "14"
  ["rss_id"]=>
  string(2) "14"
  [14]=>
  string(101) "https://www.fdanews.com/articles/190445-fda-says-505q-petitions-pull-resources-from-safety-activities"
  ["blog_url"]=>
  string(101) "https://www.fdanews.com/articles/190445-fda-says-505q-petitions-pull-resources-from-safety-activities"
  [15]=>
  string(19) "2019-03-06 06:17:24"
  ["add_date"]=>
  string(19) "2019-03-06 06:17:24"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:56"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:56"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Says 505(q) Petitions Pull Resources from Safety Activities

&#nl Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agencyâ€

array(40) {
  [0]=>
  string(4) "1947"
  ["article_id"]=>
  string(4) "1947"
  [1]=>
  string(84) "U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis"
  ["article_title"]=>
  string(84) "U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis"
  [2]=>
  string(150) "SUMMIT, N.J.--(BUSINESS WIRE)-- March 05, 2019 - Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) ha"
  ["short_description"]=>
  string(150) "SUMMIT, N.J.--(BUSINESS WIRE)-- March 05, 2019 - Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) ha"
  [3]=>
  string(248) "SUMMIT, N.J.--(BUSINESS WIRE)-- March 05, 2019 - Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority..."
  ["description"]=>
  string(248) "SUMMIT, N.J.--(BUSINESS WIRE)-- March 05, 2019 - Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(176) "https://www.drugs.com/nda/fedratinib_190305.html?utm_source=ddc&utm_medium=rss&utm_campaign=U.S.+FDA+Grants+Priority+Review+for+Fedratinib+New+Drug+Application+in+Myelofibrosis"
  ["blog_url"]=>
  string(176) "https://www.drugs.com/nda/fedratinib_190305.html?utm_source=ddc&utm_medium=rss&utm_campaign=U.S.+FDA+Grants+Priority+Review+for+Fedratinib+New+Drug+Application+in+Myelofibrosis"
  [15]=>
  string(19) "2019-03-06 05:03:29"
  ["add_date"]=>
  string(19) "2019-03-06 05:03:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

SUMMIT, N.J.--(BUSINESS WIRE)-- March 05, 2019 - Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food an

array(40) {
  [0]=>
  string(4) "2385"
  ["article_id"]=>
  string(4) "2385"
  [1]=>
  string(57) "Non-Automotive Manufacturing Sectors Flocking to Robotics"
  ["article_title"]=>
  string(57) "Non-Automotive Manufacturing Sectors Flocking to Robotics"
  [2]=>
  string(153) "&#nl        ANN ARBOR, MI—Industrial robot orders in 2018 grew 24 percent over the previous year in the life sciences, food and consumer goods, pla"
  ["short_description"]=>
  string(153) "&#nl        ANN ARBOR, MI—Industrial robot orders in 2018 grew 24 percent over the previous year in the life sciences, food and consumer goods, pla"
  [3]=>
  string(374) "&#nl        
ANN ARBOR, MI—Industrial robot orders in 2018 grew 24 percent over the previous year in the life sciences, food and consumer goods, plastics and rubber and electronics industries, according to the Robotics Industries Association. The main reasons are lower robot prices, and robot systems that are easier to install, integrate and program.
&#nl      "
  ["description"]=>
  string(374) "&#nl        
ANN ARBOR, MI—Industrial robot orders in 2018 grew 24 percent over the previous year in the life sciences, food and consumer goods, plastics and rubber and electronics industries, according to the Robotics Industries Association. The main reasons are lower robot prices, and robot systems that are easier to install, integrate and program.
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(100) "https://www.assemblymag.com/articles/94779-non-automotive-manufacturing-sectors-flocking-to-robotics"
  ["blog_url"]=>
  string(100) "https://www.assemblymag.com/articles/94779-non-automotive-manufacturing-sectors-flocking-to-robotics"
  [15]=>
  string(19) "2019-03-05 13:00:00"
  ["add_date"]=>
  string(19) "2019-03-05 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Non-Automotive Manufacturing Sectors Flocking to Robotics

&#nl

ANN ARBOR, MI—Industrial robot orders in 2018 grew 24 percent over the previous year in the life sc

array(40) {
  [0]=>
  string(4) "1948"
  ["article_id"]=>
  string(4) "1948"
  [1]=>
  string(104) "Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER"
  ["article_title"]=>
  string(104) "Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER"
  [2]=>
  string(150) "TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "
  ["short_description"]=>
  string(150) "TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "
  [3]=>
  string(245) "TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and..."
  ["description"]=>
  string(245) "TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(193) "https://www.drugs.com/nda/rexista_190304.html?utm_source=ddc&utm_medium=rss&utm_campaign=Intellipharmaceutics+Announces+Resubmission+of+New+Drug+Application+to+the+U.S.+FDA+for+its+Oxycodone+ER"
  ["blog_url"]=>
  string(193) "https://www.drugs.com/nda/rexista_190304.html?utm_source=ddc&utm_medium=rss&utm_campaign=Intellipharmaceutics+Announces+Resubmission+of+New+Drug+Application+to+the+U.S.+FDA+for+its+Oxycodone+ER"
  [15]=>
  string(19) "2019-03-05 04:03:27"
  ["add_date"]=>
  string(19) "2019-03-05 04:03:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for it

TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Inte

array(40) {
  [0]=>
  string(4) "2189"
  ["article_id"]=>
  string(4) "2189"
  [1]=>
  string(36) "17th Biosimilar Medicines Conference"
  ["article_title"]=>
  string(36) "17th Biosimilar Medicines Conference"
  [2]=>
  string(150) "For the very first time, Amsterdam, the Netherlands, will be the host city of annual Biosimilar Medicines Conference, taking place on 28th and 29th of"
  ["short_description"]=>
  string(150) "For the very first time, Amsterdam, the Netherlands, will be the host city of annual Biosimilar Medicines Conference, taking place on 28th and 29th of"
  [3]=>
  string(689) "For the very first time, Amsterdam, the Netherlands, will be the host city of annual Biosimilar Medicines Conference, taking place on 28th and 29th of March 2019. As a key milestone in the biosimilar policy agenda, this 17th edition aims at fostering a multi-stakeholder forum conducive to achieving the needed advances. Delivering biological treatments to those in need as well as unlocking re-investment opportunities in the healthcare system will concentrate participants’ attention. During these two interactive days, leaders and world […]""/"
  ["description"]=>
  string(689) "For the very first time, Amsterdam, the Netherlands, will be the host city of annual Biosimilar Medicines Conference, taking place on 28th and 29th of March 2019. As a key milestone in the biosimilar policy agenda, this 17th edition aims at fostering a multi-stakeholder forum conducive to achieving the needed advances. Delivering biological treatments to those in need as well as unlocking re-investment opportunities in the healthcare system will concentrate participants’ attention. During these two interactive days, leaders and world […]""/"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "43"
  ["rss_id"]=>
  string(2) "43"
  [14]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/O8bTb_Ccy2o/"
  ["blog_url"]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/O8bTb_Ccy2o/"
  [15]=>
  string(19) "2019-03-04 21:40:43"
  ["add_date"]=>
  string(19) "2019-03-04 21:40:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:41"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

17th Biosimilar Medicines Conference

For the very first time, Amsterdam, the Netherlands, will be the host city of annual Biosimilar Medicines Conference, ta

array(40) {
  [0]=>
  string(4) "1919"
  ["article_id"]=>
  string(4) "1919"
  [1]=>
  string(183) "Apotex Corp. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, 28x3 Blister Pack/Carton Due to Possibility of Missing/Incorrect Tablet Arrangement"
  ["article_title"]=>
  string(183) "Apotex Corp. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, 28x3 Blister Pack/Carton Due to Possibility of Missing/Incorrect Tablet Arrangement"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Weston, Florida, Apotex Corp . is voluntarily recalling four lots of Drospirenone and Ethinyl Estrad"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Weston, Florida, Apotex Corp . is voluntarily recalling four lots of Drospirenone and Ethinyl Estrad"
  [3]=>
  string(248) "Audience: Consumer, Health Professional, Pharmacy Weston, Florida, Apotex Corp . is voluntarily recalling four lots of Drospirenone and Ethinyl Estradiol Tablets, USP to the patient /user level. The four recalled lots of Drospirenone and Ethinyl..."
  ["description"]=>
  string(248) "Audience: Consumer, Health Professional, Pharmacy Weston, Florida, Apotex Corp . is voluntarily recalling four lots of Drospirenone and Ethinyl Estradiol Tablets, USP to the patient /user level. The four recalled lots of Drospirenone and Ethinyl..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/apotex-corp-issues-voluntary-nationwide-recall-drospirenone-ethinyl-estradiol-usp-28x3-blister-pack-14250.html?utm_source=ddc&utm_medium=rss&utm_campaign=Apotex+Corp.+Issues+Voluntary+Nationwide+Recall+of+Drospirenone+and+Ethinyl+Estradiol+Tablets%2C+USP%2C+28x3+Blister+Pac"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/apotex-corp-issues-voluntary-nationwide-recall-drospirenone-ethinyl-estradiol-usp-28x3-blister-pack-14250.html?utm_source=ddc&utm_medium=rss&utm_campaign=Apotex+Corp.+Issues+Voluntary+Nationwide+Recall+of+Drospirenone+and+Ethinyl+Estradiol+Tablets%2C+USP%2C+28x3+Blister+Pac"
  [15]=>
  string(19) "2019-03-04 08:00:00"
  ["add_date"]=>
  string(19) "2019-03-04 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Apotex Corp. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tabl

Audience: Consumer, Health Professional, Pharmacy Weston, Florida, Apotex Corp . is voluntarily recalling four lots of D

array(40) {
  [0]=>
  string(4) "4571"
  ["article_id"]=>
  string(4) "4571"
  [1]=>
  string(35) "4th Global Summit on Climate Change"
  ["article_title"]=>
  string(35) "4th Global Summit on Climate Change"
  [2]=>
  string(150) "On behalf of Climate Congress 2019Organizing Committee, we are pleased to invite academics, counsellors, educators, environmentalist, policy "
  ["short_description"]=>
  string(150) "On behalf of Climate Congress 2019Organizing Committee, we are pleased to invite academics, counsellors, educators, environmentalist, policy "
  [3]=>
  string(523) "On behalf of Climate Congress 2019Organizing Committee, we are pleased to invite academics, counsellors, educators, environmentalist, policy makers, research scientists, self-help group facilitators, teachers, business delegates and Young researchers across the world to attend Global Summit on Climate Change which is to be held on September 16-17, 2019 at Seoul, South Korea. The conference highlights the theme “An Insider's View of Climate Science for a Sustainable Future”.&#nlThe scientifi..."
  ["description"]=>
  string(523) "On behalf of Climate Congress 2019Organizing Committee, we are pleased to invite academics, counsellors, educators, environmentalist, policy makers, research scientists, self-help group facilitators, teachers, business delegates and Young researchers across the world to attend Global Summit on Climate Change which is to be held on September 16-17, 2019 at Seoul, South Korea. The conference highlights the theme “An Insider's View of Climate Science for a Sustainable Future”.&#nlThe scientifi..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(67) "https://www.pharmiweb.com/event/4th-global-summit-on-climate-change"
  ["blog_url"]=>
  string(67) "https://www.pharmiweb.com/event/4th-global-summit-on-climate-change"
  [15]=>
  string(19) "2019-03-01 18:36:39"
  ["add_date"]=>
  string(19) "2019-03-01 18:36:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:22"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

4th Global Summit on Climate Change

On behalf of Climate Congress 2019Organizing Committee, we are pleased to invite academics, counsellors, educat

array(40) {
  [0]=>
  string(4) "5255"
  ["article_id"]=>
  string(4) "5255"
  [1]=>
  string(23) "Pharma Conference 2019 "
  ["article_title"]=>
  string(23) "Pharma Conference 2019 "
  [2]=>
  string(158) "“19th World Pharma Congress” going to be held during November 25-26, 2019 at Singapore City, Singapore. The conference is organized with the theme"
  ["short_description"]=>
  string(158) "“19th World Pharma Congress” going to be held during November 25-26, 2019 at Singapore City, Singapore. The conference is organized with the theme"
  [3]=>
  string(524) "“19th World Pharma Congress” going to be held during November 25-26, 2019 at Singapore City, Singapore. The conference is organized with the theme “Trends, Challenges and Opportunities in Pharma Sector”. 10 different tracks with 65 sub tracks would take place to offer global knowledge that address current issues and innovations in the field of Pharma. For details, please go through https://www.meetingsint.com/conferences/pharmaFor registration, please go through: https://www.meetingsint.com/c..."
  ["description"]=>
  string(524) "“19th World Pharma Congress” going to be held during November 25-26, 2019 at Singapore City, Singapore. The conference is organized with the theme “Trends, Challenges and Opportunities in Pharma Sector”. 10 different tracks with 65 sub tracks would take place to offer global knowledge that address current issues and innovations in the field of Pharma. For details, please go through https://www.meetingsint.com/conferences/pharmaFor registration, please go through: https://www.meetingsint.com/c..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(54) "https://www.pharmiweb.com/event/pharma-conference-2019"
  ["blog_url"]=>
  string(54) "https://www.pharmiweb.com/event/pharma-conference-2019"
  [15]=>
  string(19) "2019-03-01 11:37:08"
  ["add_date"]=>
  string(19) "2019-03-01 11:37:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:27"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Pharma Conference 2019

“19th World Pharma Congress” going to be held during November 25-26, 2019 at Singapore City, Singapore. The 

array(40) {
  [0]=>
  string(4) "1921"
  ["article_id"]=>
  string(4) "1921"
  [1]=>
  string(202) "AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine/Valsartan Tablets USP and Valsartan Tablets, USP Due to the Detection of NDEA Impurity"
  ["article_title"]=>
  string(202) "AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine/Valsartan Tablets USP and Valsartan Tablets, USP Due to the Detection of NDEA Impurity"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan, and Am"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan, and Am"
  [3]=>
  string(249) "Audience: Consumer, Health Professional, Pharmacy AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan, and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an..."
  ["description"]=>
  string(249) "Audience: Consumer, Health Professional, Pharmacy AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan, and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/aurobindopharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-expansion-38-lots-14248.html?utm_source=ddc&utm_medium=rss&utm_campaign=AurobindoPharma+USA%2C+Inc.+Initiates+a+Voluntary+Nationwide+Consumer+Level+Recall+Expansion+of+38+Lots+of+Amlodipine%2FValsa"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/aurobindopharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-expansion-38-lots-14248.html?utm_source=ddc&utm_medium=rss&utm_campaign=AurobindoPharma+USA%2C+Inc.+Initiates+a+Voluntary+Nationwide+Consumer+Level+Recall+Expansion+of+38+Lots+of+Amlodipine%2FValsa"
  [15]=>
  string(19) "2019-03-01 08:00:00"
  ["add_date"]=>
  string(19) "2019-03-01 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion

Audience: Consumer, Health Professional, Pharmacy AurobindoPharma USA, Inc. is conducting a voluntary recall expansion o

array(40) {
  [0]=>
  string(4) "1920"
  ["article_id"]=>
  string(4) "1920"
  [1]=>
  string(167) "Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP"
  ["article_title"]=>
  string(167) "Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP a"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP a"
  [3]=>
  string(249) "Audience: Consumer, Health Professional, Pharmacy Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to..."
  ["description"]=>
  string(249) "Audience: Consumer, Health Professional, Pharmacy Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-usp-14249.html?utm_source=ddc&utm_medium=rss&utm_campaign=Updated%3A+Torrent+Pharmaceuticals+Limited+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+Tablets%2C+USP+and+Los"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-usp-14249.html?utm_source=ddc&utm_medium=rss&utm_campaign=Updated%3A+Torrent+Pharmaceuticals+Limited+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+Tablets%2C+USP+and+Los"
  [15]=>
  string(19) "2019-03-01 08:00:00"
  ["add_date"]=>
  string(19) "2019-03-01 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Po

Audience: Consumer, Health Professional, Pharmacy Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Lo

array(40) {
  [0]=>
  string(4) "1922"
  ["article_id"]=>
  string(4) "1922"
  [1]=>
  string(224) "Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of NMBA Impurity found in the Active Pharmaceutical Ingredient"
  ["article_title"]=>
  string(224) "Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of NMBA Impurity found in the Active Pharmaceutical Ingredient"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg t"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg t"
  [3]=>
  string(246) "Audience: Consumer, Health Professional, Pharmacy Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso..."
  ["description"]=>
  string(246) "Audience: Consumer, Health Professional, Pharmacy Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-usp-25-mg-50-mg-14246.html?utm_source=ddc&utm_medium=rss&utm_campaign=Camber+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+Tablets%2C+USP%2C+25+mg%2C+50+mg+an"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-usp-25-mg-50-mg-14246.html?utm_source=ddc&utm_medium=rss&utm_campaign=Camber+Pharmaceuticals%2C+Inc.+Issues+Voluntary+Nationwide+Recall+of+Losartan+Potassium+Tablets%2C+USP%2C+25+mg%2C+50+mg+an"
  [15]=>
  string(19) "2019-02-28 08:00:00"
  ["add_date"]=>
  string(19) "2019-02-28 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tabl

Audience: Consumer, Health Professional, Pharmacy Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets